Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. [electronic resource]
Producer: 20141118Description: 592-598 p. digitalISSN:- 1569-8041
- Antibiotics, Antineoplastic -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents, Phytogenic -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Disease-Free Survival
- Doxorubicin -- adverse effects
- Drug Administration Schedule
- Female
- Humans
- Neoplasm Metastasis -- drug therapy
- Paclitaxel -- adverse effects
- Polyethylene Glycols -- adverse effects
- Prospective Studies
- Receptor, ErbB-2 -- metabolism
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.